MHCD1406

antibody from Invitrogen Antibodies

Targeting: CD14

Provider product page for MHCD1406

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [14]
Comments [0]
Validations
Flow cytometry [1]
Other assay [8]

Submit

Product number: MHCD1406 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD14 Monoclonal Antibody (TuK4), TRI-COLOR™
Antibody type: Monoclonal
Antigen: Other
Description: The TRI-COLOR® conjugate is a tandem R-phycoerythrin (PE)-Cy5® conjugate that permits simultaneous multicolor labeling and detection of multiple targets with excitation by a single excitation source-the 488 nm line of the argon-ion laser.
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: TuK4
Vial size: 500 µL
Storage: 4° C, store in dark

CD14 protein structure - MHCD1406 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1. Targeting of IL1RAP reduces growth of human AML cells by inducing differentiation and apoptosis, without affecting healthy hematopoietic cells. (A) Cell proliferation of THP-1 AML cells with replenishment of IL1RAP polyclonal antibody (pAb). 100 ug/ml of each antibody was added at day 0 and where indicated by the symbol +. Data represent the mean +- SD of two independent experiments. P-values were calculated using unpaired two-tailed t tests, and multiple comparisons were corrected for using the Holm-Sidak method. (B) Cell proliferation of THP-1 cells treated with different doses of IL1RAP pAb. Data represent the mean +- SD of three independent experiments. P-values were calculated using unpaired two-tailed t tests and multiple comparisons were corrected for using the Holm-Sidak method. (C) Morphology of THP-1 cells after treatment with 150 ug/ml IL1RAP pAb or isotype control pAb for 24 h. (D) Expression of macrophage differentiation markers in THP-1 cells by flow cytometry 24 h after addition of 150 ug/ml IL1RAP pAb. Representative histograms are shown (top). Bar graphs (bottom) represent the mean +- SD of five independent experiments. P-values were calculated using ratio paired two-tailed t tests comparing raw MFI values of isotype control pAb- versus IL1RAP pAb-treated cells. (E) Percentage of apoptotic (annexinV + ) THP-1 cells after treatment with 150 ug/ml IL1RAP pAb for 72 h. Data represent the mean +- SD of five independent experiments. P-values were calcula

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 10.1371/journal.ppat.1008764.g002 Fig 2 Env-specific antibody binding and effector responses elicited by vaccination. (A) Serum IgG binding antibody responses to gp145 and SHIV-1157ipd3N4 antigens are shown at peak and time of challenge. Area under the curve (AUC) reflects BAMA MFI values across serially diluted serum. (B) Peak rectal binding IgG responses reported as specific activity (SA), calculated as MFI * dilution / IgG concentration. All active arm responses in (A-B) are significantly different from the control arm, but not from each other. (C) Longitudinal serum ADCC responses were assessed by antibody-dependent lysis of CFSE-labeled Env-coated target cells and are reported as an increase in CFSE-negative target cells. (D) Antibody-dependent NK cell responses were measured by Env stimulation in the presence of animal sera followed by intracellular cytokine staining (ICS) for IFNgamma, TNFalpha, and MIP1beta. The frequency of NK cells expressing one or more cytokine Boolean combinations is shown. (E) ADCP and ADNP responses were assessed using THP-1 monocyte and human neutrophil effectors, respectively. ADNP open symbol depicts animal that resisted three additional high-dose challenges. Effector assays were performed with CO6980v0c22 multimeric gp145. For ADCP and ADNP, serum was used at month 0 and plasma at months 12.7 and 15 due to sample availability. Gray bars reflect interquartile range; black lines depict medians; P values in (C-E) reflect Wilcoxon rank-sum test

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 10.1371/journal.ppat.1008764.g003 Fig 3 HIV-specific CD4 and CD8 T cell responses. (A) PBMC HIV-1 Env-specific CD4 and CD8 T cells were measured by ICS for IFNgamma, TNFalpha, IL-2, and CD154 three weeks following the third (month 6.7) and fourth (month 12.7) immunizations. The frequency of memory cells that expressed one or more cytokines following ex vivo Env PTE peptide pool stimulation is shown for each animal by arm. CD4 responses represent summation of responses to pools 1-3 (spanning amino acids 4-585), while CD8 are to pool 3 only (amino acids 413-585). (B) Bronchoalveolar lavage Env-specific CD4 and CD8 T cells were measured by ICS four weeks post-infection for animals infected by challenges one through ten. Gray bars depict interquartile range; black lines depict medians; P values reflect Wilcoxon rank-sum test.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 10.1371/journal.ppat.1008764.g004 Fig 4 Vaccine-mediated immunologic correlates of protection. (A) ADCP phagocytic (P)-scores are plotted against the challenge number that resulted in SHIV infection for male animals. Peak (month 12.5) and time of challenge (month 15) responses are shown. Unadjusted ( P )- and FDR-adjusted (q)-values reflect significance test of the continuous effects of the responses on the risk of infection (*, q

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 10.1371/journal.ppat.1008764.g005 Fig 5 Env-specific antibody-dependent phagocytic responses elicited by liposomal-MPLA-alum adjuvant in humans. (A) Serum ADCP and ADNP responses in humans vaccinated at weeks 0, 8, 24, and 72 with HIV-1 SF-2 gp120 protein adjuvanted with either alum (red) or liposomal-MPL adsorbed to alum (blue) were assessed at weeks 0 (n = 12 and 13, respectively), 26 (n = 13 each arm), and 112 (n = 11 and 9, respectively). (B) Week 26 ADCP and ADNP responses are plotted against week 26 gp120-specific binding IgG endpoint titers with Spearman's rho and P values indicated. (C) ADCP and (D) ADNP responses are stratified by participant sex to compare responses within each adjuvant study arm (left; M, male; F, female) or between arms within each sex (right). (E) gp120 IIIB Env-specific binding IgG endpoint ELISA titers are shown for all participants combined (left), by sex within each vaccine arm (middle), and by arm within each sex (right). Gray bars depict interquartile range; black lines depict medians; P values reflect Wilcoxon rank-sum test.